NCT06935370: An ongoing trial by Boehringer Ingelheim
This trial is ongoing. It must report results 3 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06935370 |
|---|---|
| Title | EASi-HF Reduced - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Chronic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) < 40% |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 20, 2025 |
| Completion date | Feb. 4, 2029 |
| Required reporting date | Feb. 4, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |